Clinical studies with more than two thousand volunteers have shown that the immunizer is effective against 100% of symptomatic cases of the disease in this age group
A Food and Drug Administration (FDA) is preparing to authorize the use of vaccine against Covid-19 developed by Pfizer–BioNTech in teenagers aged 12 to 15 until the beginning of next week. If that happens, the immunization campaign will be open to millions more people in the USA before the start of the next school year. The information is from the North American newspaper The New York Times, which cites federal officials familiar with the agency’s plans. On March 31, Pfizer and BioNTech released results of clinical trials with their vaccine that indicate that no symptomatic infections were detected in young volunteers of this age group, who produced strong antibody responses and had no serious side effects. This means that the immunizer is extremely effective in adolescents, possibly even more so than in adults. However, the use of vaccines against Covid-19 in children can generate debates about the supply being directed to an age group that until now has been more resistant to infections by new coronavirus and not, for example, to countries with worse health conditions and shortages of doses.